



中国科学院生物物理研究所

贝时璋讲座

报告题目: **New vaccine strategies using cytomegalovirus**

报告人: Prof. Klaus Früh

报告时间: 2017年11月6日(周一)10:00

报告地点: 图书馆报告厅

主持人: 邓红雨研究员



报告人简介

Dr. Klaus Früh is Professor for Molecular Microbiology and Immunology at the Vaccine and Gene Therapy Institute (VGTI) of the Oregon Health and Science University (OHSU). He is also co-founder of TomegaVax, a startup company that develops vaccine vectors using genetically modified Human Cytomegalovirus (CMV) to induce lifelong immune protection against infectious diseases and cancer. TomegaVax was recently acquired by Vir Biotechnology (www.vir.bio) a new venture that will apply breakthroughs in immune programming research to take on some of the world's most challenging infectious diseases. Dr. Früh's research focuses on understanding how pathogens evade immune clearance and to translate this knowledge into the development of novel vaccines and immunotherapies.

代表性文章

1. Natural Killer Cell Evasion Is Essential for Infection by Rhesus Cytomegalovirus. ***PLoS Pathogens* 2016**
2. Varicella Viruses Inhibit Interferon-Stimulated JAK-STAT Signaling through Multiple Mechanisms. ***PLoS Pathogens* 2015**
3. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. ***Science* 2013**
4. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. ***Science* 2010**